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Abstract 
Background: More support and education are required among mental health providers 
and clinicians regarding the use of genetic testing and pharmacogenomics as a means to 
help support psychopharmacology. Although testing for pharmacogenetics is still fairly 
new more information is needed by clinicians in order for it to be applied to practice. 
Methods: This quality improvement project took place at a psychiatric outpatient clinic 
included providers, nurses and caseworkers. After an educational intervention of 
podcast/videos and handouts were sent to participants a pre and post-test was 
administered to assess their knowledge of genetic testing. Participants were also given a 
questionnaire to assess any willingness to change and the potential for setting up genetic 
testing at the site in the future.   
Results: Out of 26 staff a total of 12 participated in the educational intervention and 
knowledge quizzes and questionnaire. The average test score increased from the pre to 
post-test score and the questionnaire responses showed positive trends as well.   
Conclusion: Staff are willing to engage with new tools, such as pharmacogenomics when 
engaged with educational tools and properly supported and monitored afterwards. 
 Keywords: pharmacogenomics, genetic testing, CYP450, psychopharmacology, 
predictive testing, drug, metabolism 
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Assessing Psychiatric Clinician Knowledge and Willingness to Utilize 
Pharmacogenomics 
Introduction 
 Over the years a number of antipsychotic and antidepressant medications have 
been developed for psychiatric patients. This has led to the development of evidence-
based practices around treatment algorithms for administering specific medication 
regimens to support improved treatment outcomes (Neiman et al., 2017). In the past five 
to ten years many advances in pharmacogenomics or genetic testing allow providers 
another way to decide on the best treatment in psychopharmacology.  
Genetic testing helps provide more targeted treatment based on a patient’s genetic 
markers and metabolism (Health Quality Ontario, 2017). Despite this recent development 
of using a patient’s DNA to help guide treatment; there was limited adoption within staff 
at the outpatient clinic for the DNP student.  
The purpose of this quality improvement project was to help educate and engage 
participants around the use of genetic testing and also it was to understand staff’s 
willingness to change and incorporate genetic testing tools into their practice in the 
future. 
Background 
The field of psychiatry has many experts following evidence-based practices to 
treat various mental illnesses. There are broad-based treatment plans with first and 
second-line medications for a variety of illnesses, which have been effective in clinical 
practice (Perese, 2012). While these treatments have been shown to be effective, 
individual patients may require treatment regimens that are tailored to their needs. Every 
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patient is different, and their bodies and genetic makeup are not always going to respond 
to medications in the same way (Lee, 2005).  
 After breakthroughs in the Genome Project there has been steady progress in the 
field of pharmacogenomics to help assist in psychopharmacotherapy to prescribe 
medications tailored to the needs of specific patients (NIH, 2019). These advances help 
avoid some of the adverse effects of psychotropic medications that may not work for a 
patient, and guide the provider to prescribe more effective medications with better 
outcomes (Aneesh et al., 2009). While there has been movement in various psychiatric 
groups to engage with this new technology for treatment, there is often a knowledge 
deficit about the fundamentals of pharmacogenetics in psychopharmacology among 
providers.  
There are many evidence-based methods of prescribing medications and engaging 
in treatment for various diagnoses, which have been established for a long time (Stein, 
2020). With many experienced psychiatrists still in the field relying on tried-and-true 
formulas it can be hard to get them to accept a new method to help prescribe effective 
treatments. Non-adherence to medication regiments that are overly complex or have 
unwanted side effects can be a problem if medications are not individually tailored 
(Neiman et al., 2017).  
While genetic testing will not fully correct medication issues, it can help 
providers to improve response rates and help support some amount of symptom remission 
over time (Greden et al., 2019). However, many providers do not have the time to invest 
in new treatment techniques if they do not feel they are fully established. There are 
assumptions often formed without direct knowledge of the new technique. Privacy 
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concerns and the risk of a patient having their personal genetic data stolen is a concern. 
Certain consumer products, like Ancestry.com and 23andMe have had mixed results with 
securing the data of their customers and not selling the data to various buyers (Molla, 
2019; Brodwin, 2018).  
With sensitive genetic data, companies that conduct genetic testing have to show 
providers that they will not create a risk for security breaches or poor practices in 
handling the data they control (Lerer et al., 2017). It is important to break through many 
of these long-held assumptions from the providers on genetic testing so that the 
effectiveness of pharmacogenomics and genetic testing as a potential tool can be utilized.  
While long-held opinions about the topic will not change overnight one issue right 
now is that many providers have not been exposed to how genetic testing works and how 
it can be applied to their daily practice in an efficient and effective manner. In these 
cases, it is important to provide support through education and teaching so that providers 
are given adequate knowledge and can then make their own judgment on the issue. 
Engagement at the staff level can help reduce the knowledge gap and give providers and 
clinicians updated treatment methods.  
Problem Statement 
 When psychiatric prescribing in outpatient and community-based settings are not 
tailored to the patient’s genetic and metabolic profiles there are increased potential for 
adverse reactions and reduced efficacy, which leads to poor outcomes for adult patients 
between 18 and 65 who have depression and schizophrenia. This often results due to lack 
of provider knowledge about research in the past five years about genetic testing tools 
and the benefits of pharmacogenomics.  
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 This quality improvement project took on this knowledge gap by engaging 
providers and clinicians as participants in direct education about what genetic testing is 
and how it can be applied to their practice. By providing individual and group education, 
utilizing videos/podcasts and informational handouts the participants were regarding 
psychopharmacological treatment and the tools available to support their practice.  
 Psychiatric staff have many treatment options available for patients. This may 
lead to newer treatments, like pharmacogenomics, not always being utilized. Most staff 
had not come in contact with genetic testing treatments or had not seen how it was used 
in clinical practice, and needed knowledge before they made practice decisions. Having 
education about new prescribing tools that cater to the individuals genetic code would 
help participants to meet that gap in providing care.  Implementing this project provided 
good value and encouraged growth in these areas.  
Review of the Literature 
Search Process 
 The main databases searched were Google Scholar, PubMed, PsychInfo, 
CINAHL, the Cochrane Library, and Web of Science.  Basic search terms started with 
genetic testing, pharmacogenomics, drug metabolism, CYP450, and 
psychopharmacology, which provided hundreds of results. When it was limited to the last 
five or six years it reduced the list to between 15-20 applicable articles. From there, the 
list was pared down to articles showing the benefits and drawbacks of genetic testing. 
Additional articles that were cited by authors not in the initial search were added. The 
main inclusion criteria were between 2015-2020 and exclusion criteria was genetic 
testing that was not related to psychiatric medications or diagnoses.  
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Fourteen out of the sixteen articles that were selected regarded genetic testing as a 
positive development with potentially useful results. There were a few negative reactions 
as well, which was necessary to be able to compare and contrast the positives and 
negatives during the provider education so that they can form an honest opinion (Lerer et 
al., 2017; Zubenko et al., 2018). It was important to show the full spectrum of opinions 
on the topic so that the capstone would not be seen as pushing one side over the other. 
Lerer et al. (2017) did a great job of laying out some of the positive aspects of the data 
generated from genetic testing, but raises objections about the need to have more 
thorough data. 
  Diagnostic tests are not often regulated as strongly as medications so there is a 
need to conduct more research around such a new diagnostic tool.  Zubenko et al. (2018) 
make similar points that the companies pushing the genetic testing are often touting 
results without thorough research. A key point is that diseases, such as Major Depressive 
Disorder (MDD), are complex in nature and often have multiple genetic and 
environmental causes, which makes it difficult to claim that genetic testing can always 
find the exact right medication (Zubenko et al., 2018). It was crucial to tailor the teaching 
towards particpants in a way that shows the tool as a support system, and not something 
that will replace their assessments and general clinical acumen. 
Genetic Testing for Major Depression Disorder  
After going through the research there were a number of trends that started to 
develop. A big trend that was noted early in the review was that a lot of the 
testing/research was about prescribing for Major Depressive Disorder and improving 
outcomes of depression (Carhart et al., 2015; Fabbri et al., 2014; Greden et al., 2019; 
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Singh, 2015).  While Carhart et al (2015) and Fabbri et al. (2014) and others were 
thorough in their approach to treating depression, their research did not highlight the 
wider scope of how genetic testing could be implemented for a variety of diagnoses in an 
outpatient setting. 
One thing that was very helpful in the Carhart et al. (2015) study was that they 
provided very detailed analysis over a one-year period to show how combining various 
genetic outcomes in the tests was able to more accurately predict what meds led to worse 
results and higher resource utilization. This could be the type of information that 
providers would like to see because it would be preventing them from wasting money on 
medications that may not be suitable for their patients.  
Some resources had a good amount of data but they were providing more of a 
review of previous data rather than doing their own study (Fabri et al., 2014).  They came 
to the conclusion that in 2014 there were genetic tests that provided clinicians with data 
to guide their practice, but they were not reliable enough to be used frequently as a 
diagnostic tool.  
This changed by the time Greden et al. (2019), released their study looking at how 
patients with depression could reduce the amount of med trials by combining provider 
assessment with genetic testing. Greden used a larger cohort of patients and double-blind 
Randomized Control Trial (RCT), which showed how patients had better results with 
their treatment when the prescriber was congruent to what the genetic test was 
recommending. This study provided much more detailed information to help understand 
that the genetic testing is a tool that will help to narrow the focus in prescribing.  
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 There was a similar increased efficacy of prescribing for Major Depressive 
Disorder when using pharmacogenomics to help provide insight and  guide practice 
(Singh, 2015). Although a smaller cohort of about one hundred fifty patients there was 
over two times increase in effectiveness when using the genetic test to support the choice 
of which antidepressant to use.  
Informational Studies Providing Baseline Knowledge 
  Genetic testing looks at the metabolic profile of many different psychiatric 
medications (Aneesh et al., 2009; Herbert et al., 2019). These studies do not have the 
same amount of research with actual patients; however, they provide a great breakdown 
of the science and history of pharmacogenomics and how it could support psychiatric 
medication (Aneesh et al., 2009). This will be crucial information to include in the pre 
and post-test along with the educational PowerPoint for the providers.  
Herbert et al. (2018), review the implementation of genetic testing via the 
IMPACT protocol in various outpatient settings. Throughout the paper they were able to 
demonstrate how this method engaged providers and involved them in incorporating the 
use of genetic testing to their practice without making them feel out of place. This 
engagement style and manner of working with the providers will be important to support 
while implementing this capstone study. It was important to try and find research articles 
that would utilize a variety of psychiatric medications as this would provide a larger 
source to pull for the research translation.  
 The variety of scenarios that can be used during research for genetic testing in 
mental health prescribing has allowed for different aspects of care, while clustering 
around a few central themes. Among many of the RCTs there was a general focus on 
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researching whether genetic testing could guide prescribing practice (Fabbri & Serretti, 
2015; Hall et al., 2012). In Fabbri and Serretti’s research (2015) they showed how genetic 
testing could provide relevant information to prescribers so that they knew what 
medications worked best for each patient. They were able to provide evidence in how 
genetic testing utilized gene and molecular pathways to find med treatments with better 
results (Fabbri & Serretti, 2015).  
This was further demonstrated by Hall-Flavin et al. (2012), who were able to 
demonstrate how the use of genetic tests provided increased effectiveness and fewer trials 
of different medications. The cohort that was provided regular treatment and multiple 
medication trials had all the medications which did not work listed on the do not use 
section of the genetic test (Hall-Flavin et al., 2012). This provided further proof of how 
genetic testing works and can further support clinical practice.  
Genetic Testing Leads to Better Prescribing 
 The randomized controlled studies provided a variety of data on genetic testing 
and how it could provide clinical data that would allow effective prescribing. Some were 
focused on the inner workings of the genetic tests and how genetic data could influence 
how individual patients were reacting to various antidepressants and antipsychotics (Altar 
et al., 2013). As more data was gathered over time the researchers were able to put more 
research into how the genetic data could provide information on metabolism of different 
drugs and patient reactions (Altar et al., 2013).  The more recent RCTs had a better 
understanding of how genetic testing worked and focused their studies on cohorts of 
patients with depression and noting whether there was a decrease in symptoms when 
genetic testing was implemented (Greden et al., 2019).  
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Evaluating the Studies 
Several studies revealed that genetic testing did reduce some of the affective 
symptoms of depression and provided treatment regimens that were different yet more 
effective than standard protocols (Greden et al., 2019; Herbert et al., 2018). These studies 
showed how implementation of a genetic testing solution with clients provided data 
showing improved rates of remission in depression, via questionnaires and patient 
reports. While the rest of the research that was collected did not have the volume of 
testing and patient engagement it was still very useful in providing data about how 
genetic testing is used and the resulting engagement.  
 The next set of studies were useful in providing detailed information on the 
clinical details of genetic testing (Fabbri et al., 2014; Singh, 2015). These studies showed 
the pharmacokinetic and pharmacodynamic underpinnings of genetic testing and how 
they could shape clinical practice. Fabbri et al. (2014) was able to examine previous 
studies using genetic testing and show how they could provide more options in treatment, 
but there was no testing of how often the options from genetic testing were reliable. 
However, these articles did not provide the same level of detail that would be necessary 
to convince providers at the outpatient site to consider genetic testing.  
The clinical guidelines offer more of a clinical review of treating MDD without 
genetic testing as an aid (American Psychiatric Association, 2010).  This was important 
in educating providers so they understand the differences between current treatment 
guidelines and genetic testing and how it can effectively supplement what they are 
already doing. Without any use of genetic testing the clinical guidelines can provide a 
good understanding for how prescribers view treatment in the community, so that there is 
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a clear delineation between previous practice and current trends with genetic testing 
complementing prescribing practice.  
Summary of Literature review 
Genetic testing can be a useful tool to provide patient-tailored med regimens that 
are more effective in practice. More research is needed to capture how genetic testing can 
be utilized in clinical settings of psychiatric practice, but there are current methods that 
can help guide providers in a safe, effective and coordinated manner. The literature 
reviews provided some context for providers on how various aspects of their practice 
could be affected if they were using genetic testing. It also offered guidance on the cost-
savings that could be realized over time and the many different avenues that the research 
could be applied to allow more understanding around the topic of genetic testing in 
psychiatric prescribing.  
Theoretical Framework 
 The underlying theoretical framework that was selected to address the knowledge 
gap for providers with genetic testing was the Roger's Diffusion and Adoption theory., It 
focuses on how to implement an innovative idea, like genetic testing, and introduce it to 
different subsets of the population to maximize interest and adoption of the treatment 
(Dearing & Cox, 2018). This theory helped guide the project to implement the new idea 
amongst the participants.  
One of the main components of the Diffusion and Adoption theory is the 
importance of knowing the audience you are working with (Kaminski, 2011). Within 
most populations there will be five different groups, innovators, early adopters, early 
majority, late majority, and laggards (Jones, 2016). The key was to know where the 
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various participants at the site fit into these groupings. Once they were identified then it 
was easier to tailor the education to those groups. There was generally not as much focus 
put on the tail ends of the s-curve (innovators and laggards) since they tend to not change.  
The innovators were excited about new technologies and would have probably 
started the adoption on their own without any support while the laggards would have 
required a lot of time-intensive education and would have needed to see many people 
adopt the new idea before they changed. While there did not appear to have been many 
innovators at this site, when the initial conversations started with staff, it was clear who 
was an innovator, as as they were the ones who responded early to the emails about the 
educational tests and questionnaires that were sent out by the DNP student.  
The “laggards” tended to be more reticent in engaging in a new technology and 
were likely not going to change their opinions for quite some time. Therefore, it was 
better to focus on the others so that they could change and slowly pull the laggards along 
with them (Sanson-Fisher, 2004). As depicted in Appendix C, the most likely way to 
succeed with moving people along was to target early adopters, early/late majority as 
they represented the bulk of the population and even though there might have been some 
push back, they were much more likely to change and adopt the new technology if given 
proper education and support.  
Once the various subsets were identified, Rogers’ theory could be used to help 
move people along to adopt the new process. Once again there are five groups or stages 
of knowledge acquisition, knowledge, persuasion, decision, implementation, and 
confirmation (Dearing & Cox, 2018). This is where the education and teaching involved 
in the project was crucial.  
 
  16 
 
 
   
 
Eventually participants were able to retain the information from utilizing it in 
their workflows so that they could go out and tout its merits to other staff (Jones, 2016). 
Roger’s theory provides a more focused and efficient manner to tackle the lack of 
information amongst staff at the site and push them towards more wide scale adoption.  
Methods 
This quality improvement project design utilized an intensive campaign to 
educate participants to create an increase in awareness and knowledge of the genetic 
testing to help select the appropriate psychotropic medication for treatment. This project 
provided more information to the participants at the site and assessed how well they were 
digesting the information and adjusting their clinical practice.  
This project ran for approximately six months, and assessed participant 
knowledge and engagement with genetic testing tools. The centerpiece of this project was 
a set of educational trainings with the providers that was done in two parts. They were 
given a few videos/podcasts that went over the basics of genetic testing.  
With information provided, both in audiovisual format and face to face they had 
more of an understanding of what the genetic testing tool was and could then participate 
in the DNP student’s assessment of their knowledge gained throughout the process.  
This helped the participant to understand what genetic testing actually looked at 
and how it was relevant to clinical practice and how the clinical tool could be utilized to 
verify what medications work better for specific patients. The individual engagement also 
offered the opportunity to display actual genetic testing kits and how they were applied in 
the field, along with the computer tools.  
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The main way that participants were assessed on their understanding of the 
concepts and tool, was done through evaluations before and after the education 
(Appendix D&F). The participants’ knowledge base was assessed with a short pre and 
post-test with multiple-choice questions that assessed how much they learned from the 
education provided (Appendix F). This was done at the start of the training and also right 
after it finished because it was important to capture how staff were feeling right after 
their training.  
Next a modified version of the Physician’s Motivation to Adoption (PMA) 
questionnaire (Appendix D), which gauged how strongly the participants felt about 
genetic testing and the potential for using it in practice, was provided to the participants 
in the project. This questionnaire helped the DNP student to understand opinions and 
beliefs of the participants towards genetic testing and how those opinions might change 
with education and teaching over time. 
The PMA scale used a Likert scale to determine how likely a provider would 
change their opinion (Hatz et al., 2017). Although this tool has typically been used to 
measure adoption of medical devices, in this project it was tailored to gauge the 
willingness of providers to take on a new treatment like genetic testing. This 
questionnaire was provided to all participants to understand how their opinions about 
genetic testing, a tool that has very rarely been used at this outpatient clinic, could have 
changed after having more education and teaching.  
Goals, Objectives and Expected Outcomes 
One goal to come out of this project was to educate participants about what 
pharmacogenetics and genetic testing are and how they could be implemented in the 
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outpatient setting. Another goal was to increase the practice of participants using genetic 
testing with patients at the site from 0% to 25% during a four-month period. Lastly, there 
was a goal to gain a better understanding of the participant’s barriers to adapt to a new 
technology, such as genetic testing in their clinical site.  
Project Site and Population   
This project focused on one outpatient facility with training specifically for the 
participants, where genetic testing in their practice could potentially help their practice. 
There were only six providers and approximately twenty nurses and caseworkers who 
were involved the genetic testing at the start of the project in September. Twelve 
participants (2 providers and 10 nurses) responded by the end of the project in January.  
Measurement Instruments 
 In order to measure the outcomes of this project the following instruments were 
used: a questionnaire in the form of the adapted PMA that helped understand how ready 
the participants were for change (Appendix D) and a multiple-choice knowledge-based 
quiz (Appendix F) that was created by the DNP student to test the participants’ 
understanding of genetic testing. This was done prior to the start of the educational 
program to get a baseline.  
The pre and posttest quiz was a way to gauge how much information the 
participant knew about genetic testing and how much they had learned throughout the 
program to see if there was an increase or decrease in their knowledge base (Appendix 
F). A quiz was specifically created to test participants’ knowledge on genetic testing for 
this project. It was created with information from research articles in the literature review 
 
  19 
 
 
   
 
along with the information from various companies about their psychopharmacological 
genetic tests. 
Data Analysis  
 This project focused on progression or regression in the knowledge base of the 
participants along with any willingness to change attitudes towards the use of genetic 
testing in their clinical practice. There were not as many participants responding as 
anticipated so less data was collected for the project than anticipated. Multiple attempts 
were made by email, phone call and face to face attempts along with using the leadership 
team at the site, but due to the pandemic with more than 50 percent of office staff 
working remote, that made engaging staff much more difficult. Therefore, descriptive 
statistics were used to describe changes. 
Ethical Considerations/Protection of Human Subjects 
The University of Massachusetts, Amherst (UMass) Internal Review Board (IRB) 
approval was obtained prior to initiating this DNP Project. It is important to note that 
although this project was conducted at an outpatient clinical site and genetic testing has a 
direct correlation to patient care, there were no patients directly involved in this project. 
The guidelines of the Health Insurance Portability and Accountability Act (HIPAA) were 
followed to protect the confidentiality and security of the participants allowing them a 
level of anonymity and hopefully allow them to express how they felt about the treatment 
and practices in an honest and straightforward manner.  
This project was meant to get the participants’ honest reactions and opinions 
about genetic testing and its application with their patients and if they felt that was not 
real then it would compromise the ethics and integrity of the entire project.  
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Results 
A total of twenty-six participants were initially engaged at the outpatient 
psychiatric clinic. The participants consisted of: six providers, which included three MDs 
and three NPs, along with twenty clinicians, which included eight nurses and twelve 
caseworkers. The documentation and education material were sent to those 26 
participants and over a period of six months, from September 2020 until February 2021, 
with twelve of the participants responding and fully engaged in the project. This meant 
that they utilized the educational materials provided and filled out the pre and posttest 
quiz along with the PMA questionnaire.  
One of the objectives of the project was to gain 50% participation of the staff at 
the clinic and with 12 participants (12/26= 46%) responding to the DNP student and 
providing all the necessary documentation that nearly met this goal.  
Participants were provided a test on basic pharmacogenetics questions to 
determine how well they understood the topic. The results are presented below:  
 
Table 1 
Change in Pre and Post-Test on Pharmacogenetics 





There was overall improvement for staff who responded to both the pre and 
posttest responses on their knowledge of pharmacogenetics. One objective in this project 
was for participants to score above 70% on the post-test after they received education on 
pharmacogenetics, which was met with an average score of 92.6% correct on the post-
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test. Staff demonstrated good understanding on their pre-test, but were able to improve on 
the post-test average score.   
Participants showed varying degrees of improvement from the pre to post-quiz 
questions. There were no questions where participants decreased their score, but there 
were some questions that showed greater improvement than others. The variety in scores 
and change in improvement was after the education intervention is illustrated in Table 2: 
Table 2 






1.(T/F) Pharmacogenetics is the study of 
individual. genetic makeup 
92 100 +8 
2. What is true about pharmacogenetics.... 66 83 +17 
3. Pharmacogenetics tests are collected via... 83 92 +9 
4. What medication classes can be tested for 92 92 +0 
5. Pharmacogenetic tests can be ordered by... 75 92 +17 
6. What is the avg. cost of pharmacogenetic 
test? 
83 83 +0 
7. (T/F) Pharmacogenetic tests only show 
results for antidepressant medications 
92 92 +0 
8. (T/F) Once given a pharmacogenetics test no 
need for future repeat test 
100 100 +0 
9. What insurance covers genetic testing in 
MA? 
92 100 +8 
10. (T/F) GINA makes it illegal for insurance 
to discriminate based on gen test info 
83 92 +9 
 
The participants were able to improve upon their scores for the majority of the 
test, which was seen in the total score increasing from an average of 85.8 to a 92.6 in the 
posttest. Participants generally did better on the true/false questions, but saw a higher 
improvement on the multiple-choice questions.  There were a few questions were 
participants saw larger score increases of more than 8 points. This is occurred on 
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questions 1,2,3,5,9, and 10. There was a mix of true/false and multiple-choice questions 
that participants improved upon from pre to post-test quiz.  
The biggest jumps in the scores were questions 2 and 5 (+17) where participants 
initially scored low and then had better scores on after their educational intervention. It's 
possible that due to these questions being more tightly focused on specific 
pharmacogenetics practices it may have been unclear at first and then with more 
education easier to answer in the post-test. In questions 9 and 10 about legal aspects of 
pharmacogenetics, reflecting their lack of knowledge, but after the educational 
intervention the participants’ scores were made some improvement.   
Next, the Physician Motivation Adoption (PMA) scale questionnaire was given , 
which was utilized with participants to understand their opinions about genetic testing 
and how likely they would adopt the tool into their practice in the future. This 
questionnaire gave a broader snapshot of the participants at the clinic and their opinions 
of pharmacogenomics and how it fit in with their clinic.  
The upcoming graphs and tables depict the results of the questionnaire and show 
how strongly the participants agree or disagree with pharmacogenomics being a part of 
the future of psychiatric care, both in their clinic and as part of their own clinical practice. 
A Likert scale with varying scales of opinion (approve, neutral, disapprove, etc) helped to 
show how participants felt about various ideas around pharmacogenomics. Table 3 is the 
first major set of questions in the PMA, which asked participants about whether they 
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Table 3 
Provider Motivation Adoption Functional Question 
 
 
Many of the participants in the clinic agreed with the statements regarding 
adopting pharmacogenomics as a means to help improve productivity and facilitate more 
clinical care. Ten out of the 12 participants answered at least Agree or Strongly agree on 
all of 4 of the Functional questions, that pharmacogenomics could potentially save more 
time, be more reliable or more practical than current practices. 
The first graph and corresponding table from the PMA questionnaire reviewed 
participants beliefs on whether they thought pharmacogenomics could help save time and 
support more reliable care, which led to much more consensus agreement among staff. In 
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the next graph and table, questions were asked regarding the interpersonal aspects of 
work environment and how pharmacogenomics may affect participants engagement with 
their peers, but there was much less agreement in this section of questions:  
            
Table 4 
Provider Motivation Adoption Conformity Question 
 
Participants had very little belief that their peer's engagement in genetic testing 
would have any effect on their involvement in it. There was a general consensus among 
participants that patients would benefit from pharmacogenomic testing which was 
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revealed in some of the questions. Most participants had no value judgement either way 
on whether they thought innovation was required in pharmacogenomics due to demands 
of a competitive workplace.  
After asking about how pharmacogenetics could benefit the participants, the 
questionnaire then sought to ask about whether participants would use genetic testing to 
support better patient care. The responses were tallied in the graph along with Table 5: 
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Participants were asked in a number of ways whether they thought 
pharmacogenomics would be able to benefit clients and a majority were in agreement that 
they could see ways it would benefit the client. More than 70 percent answered agreed or 
strongly agreed on all four of the questions in this section, indicating a strong preference 
for the belief from staff that could be a good impact on patient care long-term with 
pharmacogenomics.  
With close to a 50% response rate from the participants in the clinic that engaged 
in the initial engagement for the educational intervention on pharmacogenomics there 
was a strong response for wanting to know a new subject/tool that was not represented at 
that site. The data indicated that the participants that were engaged in the project were 
indicating a decent understanding and interest in pharmacogenomics and potential use of 
it within the clinic.  
Discussion 
Attempting to address a project in the midst of a pandemic while an outpatient 
clinic is switching to remote policies was never going to be easy. It made facilitating the 
face to face and remote engagements with staff much more challenging to try and create 
contact and explain the reason behind this project and the importance of maintaining 
contact. The desired amount of discussion among participants about pharmacogenomics 
and how it can be utilized in their practice did not occur but there was enough to show a 
way forward at the outpatient clinic.  
It was difficult to track participants down afterwards due to the pandemic, which 
is why only 12 participants ended up being utilized out of the 26 that had initially been 
sent invitations. While a small sample size this did provide data that could be utilized 
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going forward for the clinic. The majority of the participants had never encountered 
pharmacogenomics prior to the project being implemented and had not utilized it in their 
clinical practice.  
Having the educational intervention and showing the average knowledge scores 
increase above 90% was encouraging as was the general agreement that participants had 
with statements of adopting pharmacogenomics into practice in the PMA questionnaire. 
While there are always outliers in projects, it was positive to see that participants as a 
whole were willing to engage with pharmacogenomics when it was introduced during the 
education intervention and during the quiz and PMA questionnaire. There still is plenty 
of work for any adoption of the tool to occur at the site, but there was encouraging signs 
based on this project. 
When looking specifically at outcome measures, specifically the pre and post-test, 
the improvement in scores across the questions demonstrated the ability for participants 
to retain knowledge from the educational intervention and have a decent understanding of 
what pharmacogenomics and how it applies to them. It also showed an investment from 
the participants in that they were able to retain and increase that knowledge from the 
initial test to the second attempt as they were able to increase scores (or remain the same) 
across all questions.  
The motivation questionnaire revealed the shifting opinions of participants about 
pharmacogenomics, which was not a tool that was widely utilized at the start of the 
project. This clinical tool was new to the clinic and it was clear after the educational 
intervention that participants had an understanding that pharmacogenomics could be a 
practical tool. It seemed fairly clear that participants had an understanding of how genetic 
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testing could fit in with their clinical practice and save time and money compared to 
existing practices.  
There did seem to be a consensus among participants that they were not going to 
be affected by what their peers were doing with genetic testing. In answering questions 
about how much the tool was being used and the competitive nature that demanded that it 
be used at the office, there was disagreement, which seemed to show an apathy or 
disinterest at the time. It’s hard to read too much into just one questionnaire, but it would 
seem that staff were not as interested in using pharmacogenomic tools for career 
advancement and instead for its intended use of benefiting patients.   
This supported an understanding that pharmacogenomics was not necessarily a 
clinical tool of necessity, but there was some patient benefit. Participants did not agree 
how it would benefit them, or their future career, in the PMA questionnaire but they 
seemed fairly certain that pharmacogenetics could benefit patients after the education 
intervention.  
There also appeared to be an understanding among a majority of the participants 
that if genetic testing was utilized to guide some of the care, the patients would benefit 
from treatment innovation. Overall, the participant’s feelings towards genetic testing 
tended to agree with more positive and agreeable outlooks. It’s unclear if this will 
ultimately lead to a higher usage rate of genetic testing at the outpatient site, as it has not 
historically been a site to use these types of kits, but the educational intervention 
appeared to have a positive effect on the participants.   
Many of the participants at the site had minimal exposure to pharmacogenetics 
prior to this project, but they were able to increase their scores in the posttest. They also 
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had much better opinions about pharmacogenetics when they took the PMA 
questionnaire. Not every individual in the clinic shares an overall positive opinion, but as 
a whole it did appear that things were trending in a positive manner for pharmacogenetics 
and that it was more likely than not that it would be utilized by providers in the future.  
As noted in the Roger’s Diffusion Theory, as long as there are some early 
adopters that are starting to utilize the system in the clinic it could lead to more and more 
participants to adopt it. It may start slowly, but it does appear from this small project that  
there are staff who are interested in pharmacogenetic testing, which could help in moving 
it forward in the clinic in the future.  
The more participants share this knowledge and information about 
pharmacogenomics the more likely it is to grow in the future at this outpatient clinic. The 
biggest obstacle currently, is the COVID-19 pandemic, which is grounding many of 
innovations and creating many barriers for the clinic. This may not be a long-term issue, 
but it certainly will create barriers to implement a novel treatment, when more urgent 
issues such as pandemic response and staffing around the are more pressing currently. 
Hopefully in the long-term pharmacogenetic tools can be something looked at for 
providers in this outpatient clinic.    
Conclusion 
This quality improvement project was able to address a knowledge gap that 
participants had about pharmacogenetics at an outpatient psychiatric clinic. The staff had  
not been exposed to genetic testing tools and how they could be utilized in practice to 
support psychopharmacology. This education intervention was an opportunity to engage 
and support staff.  
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While outreach and engagement can be difficult there is a desire amongst staff to 
understand new tools that can be utilized when provided with education. Utilizing a 
multimedia format, staff had a better understanding of the tools for tailoring medication 
therapy based on genetics.  The Provider Motivation Adoption scale showed that 
participants were willing to bring pharmacogenomic tools in and support adopting them 
in clinical practice for a variety of reasons.  
To create lasting change among the staff there will likely need to be more hands-
on trainings and engagement with the pharmacogenetic tools over a longer period of time, 
otherwise there will not be a sustained period of time where staff will develop routines 
with the pharmacogenetic tools.  
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Appendix C 
Physician Motivation Adoption Scale (with adjustments) 
This is a screening tool used to assess motivation to change and adopt new technologies. 
This was initially created for physicians but it has been adapted to test out adoption of 
genetic testing by providers and clinicians and nurses at the outpatient clinic. This can be 
printed as a pdf or to facilitate social distancing during the era of COVID-19, this will 
also be available online at https://www.surveymonkey.com/r/ZPL5K6Q . 
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Appendix D 
Genetic Testing Education Outline 
● Encourage provider to watch genetic testing videos in person or on their own 
time. 
o Short video intro https://youtu.be/41tHL6ksNhY 
▪ Older video, gives intro to subject 
▪ Keep videos short to help providers stay focused and attentive.  
o Video podcasts intermediate length giving detailed reports of podcast 
▪ https://youtu.be/2IOMWcZ1pdE 
▪ https://youtu.be/9t5PF2ecdn4 
● Discussion with provider 
o This could be done over the phone/zoom or in person 
o What is their background in genetic testing (PGx) 
o Have they used the tests before 
o What are questions and limitations do they feel about PGx 
o What are some genetic trial options that could be used in the 
office/community? 
● Go over background of genetic testing and how it is applied in the field 
● What are possible workflows that could work for the provider 
● Review setup of genetic testing and how to incorporate practice 
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This test will be provided to providers, nurses and clinicians before engaging in 
any education and afterwards to gauge whether basic tenets of pharmacogenetics are 
understood. To facilitate social distancing during the time of COVID-19 these tests can 
also be accessed on online at https://www.surveymonkey.com/r/ZGDGP29. 
 
